L8 (tgf-beta\$ or tgfbeta)same(antibod\$) same (ards or respiratory)same(treat\$ or inhibit\$ or prevent\$ or suppress\$ or therap\$ or administ\$)	51 <u>L8</u>
<u>L7</u> L6.clm.	4 <u>L7</u>
L6 (tgf-beta\$ or tgfbeta)same(antibod\$) same (ards or respiratory or lung)same(treat\$ or inhibit\$ or prevent\$ or suppress\$ or therap\$ or administ\$)	232 <u>L6</u>
<u>L5</u> L4.clm.	0 <u>L5</u>
L4 (tgf-beta\$ or tgfbeta)same(antibod\$) same (glomerulonephritis or nephritis or diabetes)same (treat\$ or inhibit\$ or prevent\$ or suppress\$ or therap\$ or administ\$)	42 <u>L4</u>
L3 (tgf-beta\$ or tgfbeta)same(antibod\$) and (glomerulonephritis or nephritis or diabetes)	554 <u>L3</u>
$\underline{L2} L1$ and (tgf\$)	14 <u>L2</u>
L1 ruoslahti.in.	87 <u>L1</u>

END OF SEARCH HISTORY

08/3

returned.

☐ 1. 20040028682. 07 Aug 03. 12 Feb 04. Inhibiting transforming growth factor baccumulation of extracellular matrix. Border, Wayne A., et al. 424/145.1; 514/18 A6	peta to prevent 1K039/395.
 2. 20030045476. 20 Jul 01. 06 Mar 03. Heart homing conjugates. <u>Ruoslahti</u>, Erl A61K038/08. 	kki, et al. 514/16;
☐ 3. 20030032591. 21 Aug 01. 13 Feb 03. Inhibitors of cell regulatory factors and preventing or reducing scarring. Ruoslahti, Erkki I., et al. 514/12; 514/54 A61K038/1	methods for .7 A61K031/728.
☐ 4. <u>6509314</u> . 13 Jun 94; 21 Jan 03. Methods of preventing or reducing scarring voiglycan. <u>Ruoslahti</u> ; Erkki I., et al. 514/8; 514/2 530/350. A01N061/00 A61K038/17.	vith decorin or
☐ 5. <u>6436900</u> . 02 Jun 95; 20 Aug 02. Methods of treating a pathology or a fibrotic administering decorin. Ruoslahti; Erkki I., et al. 514/8; 514/12 514/2 530/350. A61K0A61K038/02 A61K038/39 C07K014/435.	condition by 038/16
\square 6. <u>6303573</u> . 07 Jun 99; 16 Oct 01. Heart homing peptides and methods of using Erkki, et al. 514/12; 424/185.1 514/14 514/16 514/2 514/21 530/300 530/324 530/32 A61K038/00.	same. <u>Ruoslahti;</u> 7 530/328 530/329.
7. 6277812.02 Jun 95; 21 Aug 01. Methods for inhibiting <u>TGFbeta.</u> activity. <u>]</u> et al. 514/2; 435/69.1 514/8 530/395. A01N061/00.	Ruoslahti; Erkki I.,
☐ 8. <u>5955578</u> . 05 Jun 95; 21 Sep 99. Polypeptide-polymer conjugates active in wo Pierschbacher; Michael D., et al. 530/345; 530/324 530/353 530/354 530/355 530/35 530/405 530/408 530/409. A61K038/00.	ound healing. 6 530/357 530/404
☐ 9. <u>5830504</u> . 01 Jun 95; 03 Nov 98. Cooperative combinations of ligands contain Vuori; Kristiina, et al. 424/484; 424/486 514/2 514/3. A61K038/04 A61K038/18 A6A61K038/28.	ned within a matrix. 1K038/20
☐ 10. <u>5705609</u> . 16 May 95; 06 Jan 98. Decorin fragments inhibiting cell regulator Ruoslahti; Erkki I., et al. 530/329; 530/324 530/399 930/10. C07K007/06 C07K014/4A61K038/17.	ry factors. 435 A61K038/08
Generate Collection Print	
Term	Documents
TGF\$	0
TGF	10728

Term	Documents
TGF\$	0
TGF	10728
TGFA	169
TGFAABMB	2
TGFAB	1
TGFAIL	1
TGFAIL*	1

11. <u>5654270</u> . 08 Sep 94; 05 Aug 97. Use of fibromodulin to prevent or reduce dermal scarring. Ruoslahti; Erkki I., et al. 514/8; 435/69.1 514/2. C07K014/435 A61K038/17.	
☐ 12. <u>5654267</u> . 30 Nov 94; 05 Aug 97. Cooperative combinations of ligands contained within a matrix. Vuori; Kristiina, et al. 514/2; 424/488 514/12 514/13 514/3 530/303 530/326 530/351 530/380 530/399. A61K038/00.	****
☐ 13. <u>5583103</u> . 14 Mar 94; 10 Dec 96. Inhibition of transforming growth factor beta activity. Ruoslahti; Erkki I., et al. 514/8; 514/2 530/350 530/380 530/399. A61K038/19 C07K014/495.	****
☐ 14. <u>5453492</u> . 28 Jul 93; 26 Sep 95. 60 kDa transforming growth factorbetabinding protein and its use to detect or purify <u>TGFbeta</u> . Butzow; Ralf, et al. 530/413; 435/7.1 530/350 530/395 530/402. C07K014/435 C07K001/22 G01N033/58.	2000